Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Period	TotalRevenue
2015-12-31	N/A
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	$500.00K
2019-12-31	$102.31M
2020-12-31	$119.07M
2021-12-31	$140.83M
2022-12-31	$214.20M
2023-12-31	$398.20M
2024-12-31	$491.73M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CPRX	$25.60	+0.00%	1.53M
3
4
5

Catalyst Pharmaceuticals Inc. (CPRX) Revenue History

Revenue Data

Get Catalyst Pharmaceuticals Inc. Data in Excel

More CPRX Financial Data